Does the media prefer BBIO or CELC?

In the previous week, BridgeBio Pharma had 8 more articles in the media than Celcuity. MarketBeat recorded 18 mentions for BridgeBio Pharma and 10 mentions for Celcuity. Celcuity's average media sentiment score of 1.20 beat BridgeBio Pharma's score of 1.17 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 13 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ASND or CELC?

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Celcuity. MarketBeat recorded 16 mentions for Ascendis Pharma A/S and 10 mentions for Celcuity. Celcuity's average media sentiment score of 1.20 beat Ascendis Pharma A/S's score of 1.13 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, EXEL or CELC?

Exelixis has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.44B 5.54 $782.57M $3.18 17.12 Celcuity N/A N/A -$177.04M -$4.30 N/A

Is EXEL or CELC more profitable?

Exelixis has a net margin of 35.33% compared to Celcuity's net margin of 0.00%. Exelixis' return on equity of 42.17% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Celcuity N/A -350.78% -41.54%

Does the media prefer EXEL or CELC?

In the previous week, Exelixis had 23 more articles in the media than Celcuity. MarketBeat recorded 33 mentions for Exelixis and 10 mentions for Celcuity. Celcuity's average media sentiment score of 1.20 beat Exelixis' score of 1.14 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 22 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BMRN or CELC?

In the previous week, BioMarin Pharmaceutical had 9 more articles in the media than Celcuity. MarketBeat recorded 19 mentions for BioMarin Pharmaceutical and 10 mentions for Celcuity. BioMarin Pharmaceutical's average media sentiment score of 1.59 beat Celcuity's score of 1.20 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 17 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Celcuity 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARWR or CELC?

In the previous week, Arrowhead Pharmaceuticals had 9 more articles in the media than Celcuity. MarketBeat recorded 19 mentions for Arrowhead Pharmaceuticals and 10 mentions for Celcuity. Arrowhead Pharmaceuticals' average media sentiment score of 1.47 beat Celcuity's score of 1.20 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 14 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Celcuity (CELC) Competitors

$88.44 -4.80 (-5.15%)

As of 08/28/2026 04:00 PM Eastern

Compare

CELC vs. BBIO, ASND, EXEL, BMRN, and ARWR

Should you buy Celcuity stock or one of its competitors? Celcuity's main competitors and comparable companies include BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), and Arrowhead Pharmaceuticals (ARWR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Celcuity compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

BridgeBio Pharma has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Celcuity has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

In the previous week, BridgeBio Pharma had 8 more articles in the media than Celcuity. MarketBeat recorded 18 mentions for BridgeBio Pharma and 10 mentions for Celcuity. Celcuity's average media sentiment score of 1.20 beat BridgeBio Pharma's score of 1.17 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	13 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Pharma presently has a consensus target price of $100.79, suggesting a potential upside of 31.58%. Celcuity has a consensus target price of $154.55, suggesting a potential upside of 74.75%. Given Celcuity's higher possible upside, analysts plainly believe Celcuity is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

99.8% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 63.3% of Celcuity shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 13.3% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Celcuity has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$713.07M	21.00	-$724.93M	-$3.57	N/A
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

Celcuity has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Celcuity	N/A	-350.78%	-41.54%

Summary

BridgeBio Pharma beats Celcuity on 9 of the 15 factors compared between the two stocks.

How does Celcuity compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Celcuity. MarketBeat recorded 16 mentions for Ascendis Pharma A/S and 10 mentions for Celcuity. Celcuity's average media sentiment score of 1.20 beat Ascendis Pharma A/S's score of 1.13 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 70.99% compared to Celcuity's net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Celcuity	N/A	-350.78%	-41.54%

Ascendis Pharma A/S currently has a consensus price target of $302.68, indicating a potential upside of 22.09%. Celcuity has a consensus price target of $154.55, indicating a potential upside of 74.75%. Given Celcuity's higher probable upside, analysts clearly believe Celcuity is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.05
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

63.3% of Celcuity shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 13.3% of Celcuity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Celcuity has lower revenue, but higher earnings than Ascendis Pharma A/S. Celcuity is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	18.99	-$258M	$12.89	19.23
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

Ascendis Pharma A/S has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Celcuity has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats Celcuity on 12 of the 16 factors compared between the two stocks.

How does Celcuity compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

85.3% of Exelixis shares are held by institutional investors. Comparatively, 63.3% of Celcuity shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Comparatively, 13.3% of Celcuity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Exelixis currently has a consensus price target of $50.07, indicating a potential downside of 8.05%. Celcuity has a consensus price target of $154.55, indicating a potential upside of 74.75%. Given Celcuity's stronger consensus rating and higher possible upside, analysts plainly believe Celcuity is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Exelixis has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.44B	5.54	$782.57M	$3.18	17.12
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

Exelixis has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Celcuity has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

Exelixis has a net margin of 35.33% compared to Celcuity's net margin of 0.00%. Exelixis' return on equity of 42.17% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Celcuity	N/A	-350.78%	-41.54%

In the previous week, Exelixis had 23 more articles in the media than Celcuity. MarketBeat recorded 33 mentions for Exelixis and 10 mentions for Celcuity. Celcuity's average media sentiment score of 1.20 beat Exelixis' score of 1.14 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	22 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Exelixis beats Celcuity on 11 of the 16 factors compared between the two stocks.

How does Celcuity compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

BioMarin Pharmaceutical has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Celcuity has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market.

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 63.3% of Celcuity shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 13.3% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, BioMarin Pharmaceutical had 9 more articles in the media than Celcuity. MarketBeat recorded 19 mentions for BioMarin Pharmaceutical and 10 mentions for Celcuity. BioMarin Pharmaceutical's average media sentiment score of 1.59 beat Celcuity's score of 1.20 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	17 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Celcuity	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical currently has a consensus price target of $88.79, suggesting a potential upside of 37.30%. Celcuity has a consensus price target of $154.55, suggesting a potential upside of 74.75%. Given Celcuity's stronger consensus rating and higher possible upside, analysts plainly believe Celcuity is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

BioMarin Pharmaceutical has a net margin of 2.14% compared to Celcuity's net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Celcuity	N/A	-350.78%	-41.54%

BioMarin Pharmaceutical has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.41B	3.67	$348.90M	$0.37	174.78
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

Summary

BioMarin Pharmaceutical beats Celcuity on 13 of the 16 factors compared between the two stocks.

How does Celcuity compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

In the previous week, Arrowhead Pharmaceuticals had 9 more articles in the media than Celcuity. MarketBeat recorded 19 mentions for Arrowhead Pharmaceuticals and 10 mentions for Celcuity. Arrowhead Pharmaceuticals' average media sentiment score of 1.47 beat Celcuity's score of 1.20 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	14 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market.

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 63.3% of Celcuity shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 13.3% of Celcuity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Arrowhead Pharmaceuticals presently has a consensus target price of $97.33, suggesting a potential upside of 14.63%. Celcuity has a consensus target price of $154.55, suggesting a potential upside of 74.75%. Given Celcuity's stronger consensus rating and higher probable upside, analysts clearly believe Celcuity is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Arrowhead Pharmaceuticals has higher revenue and earnings than Celcuity. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.42	-$1.63M	-$2.25	N/A
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

Celcuity has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Arrowhead Pharmaceuticals' return on equity of -60.06% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Celcuity	N/A	-350.78%	-41.54%

Summary

Arrowhead Pharmaceuticals beats Celcuity on 8 of the 15 factors compared between the two stocks.

Get Celcuity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CELC vs. The Competition

Export

Metric	Celcuity	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.33B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-20.57	11.62	273.16	25.45
Price / Sales	N/A	1,295.88	605.00	76.62
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	-340.15	16.53	12.98	6.14
Net Income	-$177.04M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-5.44%	-0.31%	0.13%	-0.80%
1 Month Performance	0.91%	9.80%	7.08%	4.13%
1 Year Performance	72.63%	55.66%	24.67%	15.17%

Celcuity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELC Celcuity	2.7597 of 5 stars	$88.44 -5.1%	$154.55 +74.7%	+72.6%	$4.33B	N/A	N/A	40	News Coverage Positive News
BBIO BridgeBio Pharma	3.4598 of 5 stars	$80.73 -0.4%	$100.79 +24.8%	+48.0%	$15.81B	$502.08M	N/A	400	Positive News
ASND Ascendis Pharma A/S	4.7031 of 5 stars	$252.91 +0.4%	$300.33 +18.7%	+27.6%	$15.79B	$814.57M	19.64	1,189	Analyst Forecast Analyst Revision
EXEL Exelixis	3.1006 of 5 stars	$55.97 +2.6%	$50.07 -10.5%	+45.5%	$13.87B	$2.32B	17.60	1,077	Trending News Options Volume Analyst Revision
BMRN BioMarin Pharmaceutical	4.9111 of 5 stars	$66.18 +1.7%	$88.83 +34.2%	+11.0%	$12.80B	$3.22B	178.79	3,221	News Coverage Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CELC) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Celcuity (CELC) Competitors

CELC vs. BBIO, ASND, EXEL, BMRN, and ARWR

How does Celcuity compare to BridgeBio Pharma?

Summary

How does Celcuity compare to Ascendis Pharma A/S?

Summary

How does Celcuity compare to Exelixis?

Summary

How does Celcuity compare to BioMarin Pharmaceutical?

Summary

How does Celcuity compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELC vs. The Competition

Celcuity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Celcuity (CELC) Competitors

CELC vs. BBIO, ASND, EXEL, BMRN, and ARWR

How does Celcuity compare to BridgeBio Pharma?

Which has more volatility & risk, BBIO or CELC?

Does the media prefer BBIO or CELC?

Do analysts prefer BBIO or CELC?

Do insiders and institutionals have more ownership in BBIO or CELC?

Which has better valuation and earnings, BBIO or CELC?

Is BBIO or CELC more profitable?

Summary

How does Celcuity compare to Ascendis Pharma A/S?

Does the media refer more to ASND or CELC?

Is ASND or CELC more profitable?

Do analysts prefer ASND or CELC?

Do insiders & institutionals believe in ASND or CELC?

Which has better valuation and earnings, ASND or CELC?

Which has more risk & volatility, ASND or CELC?

Summary

How does Celcuity compare to Exelixis?

Do institutionals & insiders believe in EXEL or CELC?

Do analysts prefer EXEL or CELC?

Which has stronger valuation & earnings, EXEL or CELC?

Which has more risk and volatility, EXEL or CELC?

Is EXEL or CELC more profitable?

Does the media prefer EXEL or CELC?

Summary

How does Celcuity compare to BioMarin Pharmaceutical?

Which has more volatility and risk, BMRN or CELC?

Do institutionals and insiders have more ownership in BMRN or CELC?

Does the media refer more to BMRN or CELC?

Do analysts recommend BMRN or CELC?

Is BMRN or CELC more profitable?

Which has stronger earnings and valuation, BMRN or CELC?

Summary

How does Celcuity compare to Arrowhead Pharmaceuticals?

Does the media refer more to ARWR or CELC?

Which has more volatility & risk, ARWR or CELC?

Do institutionals and insiders believe in ARWR or CELC?

Do analysts prefer ARWR or CELC?

Which has higher valuation and earnings, ARWR or CELC?

Is ARWR or CELC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELC vs. The Competition

Celcuity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools